First Latin American position paper on the pharmacological treatment of rheumatoid arthritis

Rheumatology

Volumn 45, Issue SUPPL. 2, 2006, Pages

  Cardiel, Mario H ^a  

^a Dr Mario Alvizouri Muñoz Hospital General   (Mexico)

Author keywords

Diagnosis; Epidemiology; Latin America; Rheumatoid arthritis; Therapy

Indexed keywords

AZATHIOPRINE; BETAMETHASONE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CHLOROQUINE; CYCLOSPORIN A; DEFLAZACORT; DEXAMETHASONE; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD; HYDROXYCHLOROQUINE; IBUPROFEN; INDOMETACIN; KETOPROFEN; LEFLUNOMIDE; MELOXICAM; METHOTREXATE; METHYLPREDNISOLONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISOLONE; PREDNISONE; RITUXIMAB; ROFECOXIB; SALAZOSULFAPYRIDINE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VITAMIN D; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT;

ADVISORY COMMITTEE; ALOPECIA; ANAPHYLAXIS; ANOREXIA; ARTICLE; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; CONSENSUS DEVELOPMENT; CORTICOSTEROID INDUCED OSTEOPOROSIS; CYTOPENIA; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; EARLY DIAGNOSIS; ETHNOLOGY; EXERCISE; EYE TOXICITY; GASTROINTESTINAL SYMPTOM; GENETIC SUSCEPTIBILITY; GINGIVA HYPERPLASIA; HEADACHE; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEMATURIA; HEREDITY; HIRSUTISM; HUMAN; HYPERPIGMENTATION; HYPERTENSION; HYPERTRICHOSIS; INFECTION; JOINT RADIOGRAPHY; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER TOXICITY; LYMPHOPROLIFERATIVE DISEASE; MANPOWER; MEDICAL DOCUMENTATION; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDICAL RECORD; MORTALITY; MOUTH ULCER; MUCOSA INFLAMMATION; MULTIPLE SCLEROSIS; MYOPATHY; NAUSEA; NEPHROTIC SYNDROME; OCCUPATIONAL THERAPY; ORTHOPEDIC SURGERY; PANCREATITIS; PHOTOSENSITIVITY; PHYSIOTHERAPY; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL STANDARD; PROGNOSIS; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SOUTH AND CENTRAL AMERICA; STOMATITIS; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUBERCULOSIS; CENTRAL AMERICA; CONFERENCE PAPER; MEDICAL SOCIETY; RHEUMATOLOGY;

ANTIMALARIALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARIBBEAN REGION; HUMANS; LATIN AMERICA; METHOTREXATE; RHEUMATOLOGY; SOCIETIES, MEDICAL;

EID: 33747044702     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kei500     Document Type: Article

References (154)

1. Callegari-Jacques SM, Grattapaglia D, Salzano FM et al. Historical genetics: Spatiotemporal analysis of the formation of the Brazilian population. Am J Hum Biol 2003;15:824-34.
2. Lisker R, Ramirez E, Briceño RP. Gene frequencies and admixture estimates in four Mexican urban centers. Hum Biol 1990;62:791-801.
3. Sans M, Salzano FM, Chakraborty R. Historical genetics in Uruguay: estimates of biological origins and their problems. Hum Biol 1997;69:161-70.
4. Kliksberg B. Social scenarios in Latin America and the Caribbean. Rev Panam Salud Pública 2000;8:105-11.
5. Organización Panamericana de la Salud. La Salud en las Américas. In: Salud OPdl, ed. Publicación científica y técnica No 587. Vol. 1. Washington, DC: Organización Mundial de la Salud, 2002.
6. Sihvonen S, Korpela M, Laippala P, Mustonen J, Pasternack A. Death rates and causes of death in patients with rheumatoid arthritis: A population-based study. Scand J Rheumatol 2004;33:221-7.
7. Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: An international long-term view. Semin Arthritis Rheum 2000;29:305-20.
8. Keystone E. Tumor necrosis factor-α blockade in the treatment of rheumatoid arthritis. Rheum Dis Clin NA 2001;27:427-43.
9. Ministerio de Salud de Chile. Los objetivos sanitarios para la década 2000-2010. Santiago: Ministerio de Salud de Chile. Gobierno de Chile, 2002.
10. Abdel-Nasser AM, Rasker JJ, Valkenburg HA. Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis. Sernin Arthritis Rheum 1997;27:123-40.
11. Spindler A, Bellomio V, Berman A et al. Prevalence of rheumatoid arthritis in Tucuman, Argentina. J Rheumatol 2002;29:1166-70.
12. Senna ER, De Barros AL, Silva EO et al. Prevalence of rheumatic diseases in Brazil: A study using the COPCORD approach. J Rheumatol 2004;31:594-7.
13. Cardiel MH, Rojas-Serrano J. Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study. Clin Exp Rheumatol 2002;20:617-24.
14. Pons-Estel BA, Catoggio LJ, Cardiel MH et al. The GLADEL multinational Latin American prospective inception cohort of 1214 patients with systemic lupus erythematosus: Ethnic and disease heterogeneity among "Hispanics". Medicine (Baltimore) 2004;83:1-17.
15. Fraser PA, Yunis EJ, Alper CA. Excess admixture proportion of extended major histocompatability complex haplotypes of Caucasian origin among rheumatoid arthritis associated haplotypes in African Americans and Afro-Caribbeans. Ethn Health 1996;1:153-9.
16. Massardo L, Aguirre V, García ME et al. Clinical expression of rheumatoid arthritis in Chilean patients. Semin Arthritis Rheum 1995;25:203-13.
17. Anaya JM, Correa PA, Mantilla RD et al. Rheumatoid arthritis in African Colombians from Quibdo. Semin Arthritis Rheum 2001; 31:191-8.
18. Angulo J, Miraval T, Ponce de León H et al. Epitope Reumatoide y alelo HLA-DRB1*0404 se asocian con susceptibilidad para artritis reumatoide en mestizos peruanos, alelo HLA-DRB1*1402 en duda y la combinación maligna *0401/0404 ausente. Revista Peruana de Reumatología 2003;9:26-32.
19. Ruiz-Morales JA, Vargas-Alarcon G, Flores-Villanueva PO et al. HLA-DRB1 alleles encoding the "shared epitope" are associated with susceptibility to developing rheumatoid arthritis whereas HLA-DRB1 alleles encoding an aspartic acid at position 70 of the β-chain are protective in Mexican Mestizos. Hum Immunol 2004;65:262-9.
20. Citera G, Padulo LA, Fernandez G et al. Influence of HLA-DR alleles on rheumatoid arthritis: Susceptibility and severity in Argentine patients. J Rheumatol 2001;28:1486-91.
21. Cadena J, Vinaccia S, Pérez A, Hinojosa R, Anaya JM. The impact of disease activity on the quality of life, mental health status, and family dysfunction in Colombian patients with Rheumatoid Arthritis. J Clin Rheumatol 2003;9:142-50.
22. Concha M, Aguilera X, Salas J. La carga de enfermedad en Chile. Proyecto de Prioridades de inversión en Salud. Ministerio de Salud, República de Chile. Santiago de Chile, 1996:1-62.
23. Martínez I. Costos de la Artritis Reumatoide en Venezuela. Reumatología. Caracas: Universidad Bolivariana, 1997.
24. Ariza-Ariza R, Mestanza-Peralta M, Cardiel MH. Direct costs of medical attention to Mexican patients with rheumatoid arthritis in a tertiary care center. Clin Exp Rheumatol 1997;15:75-8.
25. Audisio MJ, Strusberg I, Orellana Barrera SD et al. Semester direct cost by rheumatoid arthritis in patients in a university hospital. Rev Fac Cien Med Univ Nac Cordoba 2003;60:35-41.
26. American College of Rheumatology subcommittee on Rheumatology Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328-46.
27. Emery P. Evidence supporting the benefit of early intervention in rheumatoid arthritis. J Rheumatol 2002;29 (Suppl 66):3-8.
28. Emery P. Is it time for a European Consensus on the pharmacological management of early RA? J Rheumatol 2002;29 (Suppl 66):1-2.
29. Bresnihan B. Rheumatoid arthritis: Principles of early treatment. J Rheumatol 2002;29 (Suppl 66):9-12.
30. Wolfe F. The natural history of rheumatoid arthritis. J Rheumatol 1996;23:13-22.
31. Dechant SA, Matteson EL. Managing comorbidity risks in rheumatoid arthritis. Curr Op Rheum 2004;16:177-9.
32. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Occurrence of extra-articular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002;29:62-7.
33. Nicola PJ, Maradit-Kremers H, Roger VL et al. The risk of congestive heart failure in rheumatoid arthritis: A population-based study over 46 years. Arthritis Rheum 2005;52:412-20.
34. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: A population-based study. Arthritis Rheum 2005;52:722-32.
35. Fries JF, Williams CA, Morfeld D, Singh E, Sibley J. Reduction in long term disability in patients with rheumatoid arthritis by disease modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 1996;39:616-22.
36. Stenger AA, van Leeuwen MA, Houtman PM et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol 1998;37:1157-63.
37. Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 2003;48:1771-4.
38. Kim J. Weisman M. When does rheumatoid arthritis begin and why do we need to know? Arthritis Rheum 2000;43:473-84.
39. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
40. Harrison BJ, Symmons DM, Barnett EM, Young DY, Fries JF. The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. J Rheumatol 1998;25:2324-30.
41. Sherrer YS, Bloch DA, Mitchell DM et al. The development of disability in rheumatoid arthritis. Arthritis Rheum 1986;29:494-500.
42. Pincus T, Callahan LF. Remodeling the pyramid or remodeling the paradigms concerning rheumatoid arthritis: Lessons from Hodgkin's disease and coronary artery disease. J Rheumatol 1990;17:1582-5.
43. Scott DL. Prognostic factors in early rheumatoid arthritis. Rheumatology (Oxford) 2000;39 (Suppl 1):24-9.
44. van Zeben D, Hazes JM, Zwiderman AH et al. Factors predicting outcome of rheumatoid arthritis: Results of a follow up study. J Rheumatol 1993;20:1288-96.
45. van Riel PLCM, van Gestel AM, van De Putte LBA. Development and validation of response criteria in rheumatoid arthritis: Steps towards an international consensus on prognostic markers. Br J Rheumatol 1996;35:4-7.
46. van der Heijide DM, van Riel PL, van Leeuwen MA et al. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 1992;31:519-25.
47. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis. The importance of disease duration. Arthritis and Rheum 2000;43:22-29.
48. In: www.dasscore.nl. Last accessed: 09/13/2005.
49. Lopez-Ben R, Bernreuter WK, Moreland LW, Alarcon GS. Ultrasound detection of bone erosions in rheumatoid arthritis: A comparison to routine radiographs of the hands and feet. Skeletal Radiol 2004;33:80-4.
50. Terslev L, Torp-Pedersen S, Savnik A et al. Doppler ultrasound and magnetic resonance imaging of synovial inflammation of the hand in rheumatoid arthritis: A comparative study. Arthritis Rheum 2003;48:2434-41.
51. Tehranzadeh J, Ashikyan O, Dascalos J. Magnetic resonance imaging in early detection of rheumatoid arthritis. Semin Musculoskelet Radiol 2003;7:79-94.
52. Goldbach-Mansky R, Lee J, McCoy A et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000;2:236-43.
53. van Jaarsveld CH, ter Borg EJ, Jacobs JW et al. The prognostic value of the antiperinuclear factor, anti-citrullinated peptide anti-bodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol 1999;17:689-97.
54. Kroot EJ, de Jong BA, van Leeuwen MA et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
55. Gough A, Faint J, Salmon M et al. Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum 1980;23:137-45.
56. Massardo L, Gareca N, Cartes MA, Cervilla V, Gonzalez A, Jacobelli S. The presence of the HLA-DRB1 shared epitope correlates with erosive disease in Chilean patients with rheumatoid arthritis. Rheumatology (Oxford) 2002;41:153-6.
57. Debaz H, Olivo A, Vazquez Garcia MN et al. Relevant residues of DRbeta1 third hypervariable region contributing to the expression and to severity of rheumatoid arthritis (RA) in Mexicans. Hum Immunol 1998;59:287-94.
58. Castro F, Acevedo E, Ciusani E et al. Tumour necrosis factor microsatellites and HLA-DRB1*, HLA-DQA1*, and HLA-DQB1* alleles in Peruvian patients with rheumatoid arthritis. Ann Rheum Dis 2001;60:791-5.
59. Gabriel SE, Crowson CS, O'Fallon WM. Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol 1999;26:2529-33.
60. Breedveld FC, Kalden JR. Appropriate and effective management of rheumatoid arthritis. Ann Rheum Dis 2004;63:627-33.
61. Cisternas M, Gutierrez MA, Klaassen J, Acosta AM, Jacobelli S. Cardiovascular risk factors in Chilean patients with rheumatoid arthritis. J Rheumatol 2002;29:1619-22.
62. Navarro-Cano G, Del Rincon I, Pogosian S, Roldan JF, Escalante A. Association of mortality with disease severity in rheumatoid arthritis, independent of comorbidity. Arthritis Rheum 2003;48:2425-33.
63. del Rincon I, Escalante A. Atherosclerotic cardiovascular disease in rheumatoid arthritis. Curr Rheumatol Rep 2003;5:278-86.
64. Del Rincon I, Williams K, Stern MP, Freeman GL, O'Leary DH, Escalante A. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003;48:1833-40.
65. Dursunoglu D et al. Lipoprotein and lipids in patients with rheumatoid arthritis: Serum levels and relationship to inflammation. Rheumatol Int 2005;25:241-5.
66. Yoo WH. Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex and menopausal status. J Rheumatol 2004;31:1746-53.
67. Bacon PA et al. The role of endothelial cell dysfunction in the cardiovascular mortality of RA. Int Rev Immunol 2002;21:1-17.
68. Goodson N. Coronary artery disease and rheumatoid arthritis. Curr Opin Rheumatol 2002;14:115-20.
69. Felson DT, Anderson JJ, Boers M et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36:729-40.
70. Felson DT, Anderson JJ, Boers M et al. The American College of Rheumatology Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
71. van Gestel AM, Prevoo ML, van't Hof MA, van Rijwik MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American college of Rheumatology and the World Health Organization/International League against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
72. Boers M. The case for corticosteroids in the treatment of early rheumatoid arthritis. Rheumatology (Oxford) 1999;38:95-7.
73. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: Clinical efficacy, disease-modifying properties, and side effects: A randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002;136:1-12.
74. Townsend HB, Sag KG. Glucocorticoid use in rheumatoid arthritis: benefits, mechanisms, and risks. Clin Exp Rheumatol 2004;22 (Suppl 35);S77-82.
75. Pincus T, Sokka T, Stein CM. Are long-term very low doses of prednisone for patients with rheumatoid arthritis as helpful as high doses are harmful? Ann Intern Med 2002;136:76-8.
76. Choy EH, Kingsley GH, Corkill MM. Intramuscular methylprednisolone is superior to pulse oral methylprednisolone during the induction phase of chrysotherapy. Br J Rheumatol 1993;32:734-9.
77. Sambrokk PN. How to prevent steroid induced osteoporosis. Ann Rheum Dis 2005;64:176-8.
78. Joint statement of the ATS CDC and endorsed by the council of the infectious diseases society of America. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Resp Crit Care Med 2000;161:S221-47.
79. Hernández-Cruz B, Cardiel MH, Villa AR, Alcocer-Varela J. Development and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study. J Rheumatol 1998;25:1900-7.
80. Santana-Sabagún E, Weisman MH. Nonsteroidal anti-inflamatory drugs. In: Rudy S, Harris ED,Jr Sledge CB, eds. Kelly's texbook of Rheumatology. Philadelphia: WB Saunders Company, 2001: 799-822.
81. Brooks P. Non-steroidal anti-inflammatory drugs. In: Hochberg M, Silman AJ, Smolen JS, Weinblatt M, Weisman M, eds. Rheumatology, 3rd edn. Edinburgh: Mosby, 2003:377-84.
82. Simon LS, Weaver AL, Graham DY et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial. JAMA 1999;282:1921-8.
83. Smolen JS, Aletaha D, Machold KP. Therapeutic strategies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2005; 19:163-77.
84. Dougados M, Smolen JS. Pharmacological management of early rheumatoid arthritis-does combination therapy improve outcomes? J Rheumatol Suppl 2002;66:20-6.
85. Bennett AN, Peterson P, Zain A, Grumley J, Panayi G, Kirkham B. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology (Oxford) 2005 May 3; [Epub ahead of print].
86. van der Heijde D, Klareskog L, Boers M et al. For The Tempo Investigators S. Comparison of different definitions to classify remission and sustained remission: One year TEMPO results. Ann Rheum Dis 2005 May 18; [Epub ahead of print].
87. Quinn MA, Conaghan PG, O'Connor PJ et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:27-35.
88. Pincus T. Aggressive treatment of early rheumatoid arthritis to prevent joint damage. Bull Rheum Dis 1998;47:2-7.
89. Rau R, Herborn G. Benefit and risk of methotrexate treatment in rheumatoid arthritis. Methotrexate produces more sustained responses over time than other DMARDs, such as sulphasalazine, parenteral gold, and hydroxychloroquine. Clin Exp Rheumatol 2004;22(5 Suppl 35):S83-94.
90. Pisetsky DS, St Clair EW. Progress in the treatment of rheumatoid arthritis. Sulphasalazine (SSZ) has been shown to be mostly used in patients with lower disease activity. JAMA 2001;286:2787-90.
91. Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) 2002;41:1367-74.
92. Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999:159;2542-50.
93. Ward JR. Role of disease-modifying antirheumatic drugs versus cytotoxic agents in the therapy of rheumatoid arthritis. Am J Med 1988;85:39-44.
94. Wick MC, Lindblad S, Weiss RJ et al. Estimated prediagnosis radiological progression: An important tool for studying the effects of early disease modifying antirheumatic drug treatment in rheumatoid arthritis. Ann Rheum Dis 2005;64:134-7.
95. Turesson C, Matteson EL. Management of extra-articular disease manifestations in rheumatoid arthritis. Curr Opin Rheumatol 2004; 16:206-11.
96. Suarez-Almazor ME, Spooner C, Belseck E. Penicillamine for treating rheumatoid arthritis. Cochrane Database Syst Rev 2000;4: CD001460.
97. Lehman AJ, Esdaile JM, Klinkhoff AV et al. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: Results of the METGO study. Arthritis Rheum 2005;52:1360-70.
98. Rau R, Herborn G, Menninger H et al. Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients. Rheumatology (Oxford) 2002;41:196-204.
99. Aletaha D, Smolen JS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol 2002;29:1631-8.
100. Pope JE, Hong P, Koehler BE. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: A survey of practicing Canadian rheumatologists. J Rheumatol 2002; 29:255-60.
101. Johns KR, Littlejohn GO. The safety and efficacy of ciclosporine (Neoral) in rheumatoid arthritis. J Rheumatol 1999;26:2110-3.
102. Schiff MH, Whelton A. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis. Semin Arthritis Rheum 2000;30:196-208.
103. Zerkak D, Dougados M. Benefit/risk of combination therapies. Chn Exp Rheumatol 2004;22(5 Suppl 35):S71-6.
104. Maini R, Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor-α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate therapy: A randomized phase III trial ATTRACT study Group. Lancet 1999;354:1932-9.
105. Moreland LW. Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol 199;26:7-15.
106. Harriaman G, Harper LK, Schaible TF. Summary of clinical trials in rheumatoid arthritis using infliximab an anti TNF-alpha treatment. Ann Rheum Dis 1999;58(Suppl 1):161-4.
107. Furst DE, Breedveld FC, Kalden JR et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases. Ann Rheum Dis 2003;62(Suppl 2)ii2-9.
108. van de Putte LB, Atkins C, Malaise M et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16.
109. Markham A, Lamb HM. Infliximab: A review of its use in the management of rheumatoid arthritis. Drugs 2000;59:1341-59.
110. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
111. Kavanaugh AF. Anti-tumor necrosis factor-α monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am 199824:593-614.
112. Furst DE, Schiff MH, Fleischmann RM et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-71.
113. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;34:253-69.
114. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
115. Weinblatt ME, Keystone EC, Furst DE. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003;48:35-45.
116. Cush J. Cytokine therapies. In: Hochberg M, Silman AJ, Smolen JS, Weinblatt M, Weisman M, eds. Rheumatology, 3rd edn. Edinburgh: Mosby, 2003:461-89.
117. Voll RE, Kalden JR. Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis? Ann N Y Acad Sci 2005;1051:799-810.
118. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
119. Pollard L, Choy E. Rheumatoid arthritis: Non-tumor necrosis factor targets. Curr Opin Rheumatol 2005;17:242-6.
120. Edwards JC, Cambridge G. Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology 2005;44:151-6.
121. Kremer JM, Dougados M, Emery P et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept. Athritis Rheum 2005;52:2263-71.
122. NICE. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. Technology Appraisal No. 36. Reviewed. March 2005.
123. Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF. Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): Results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 2005; 34:353-8.
124. Burmester GR, Monteagudo Saez I, Malaise MG et al. Adalimumab (Humira®) is effective in patients who have previously been treated with TNF-antagonists (Etanercept and/or Infliximab) in widespread clinical practice: 12-week outcomes in the REACT trial. Ann Rheum Dis 2005;64(Suppl III):423-4 (Poster SAT0047).
125. Bombardieri S, Tzioufas AG, McKenna F et al. Adalimumab (Humira®) is effective in treating patients with rheumatoid arthritis who previously failed etanercept and/or infliximab in real-life clinical settings. Arthritis Rheum 2005;52(9 Suppl):S144 (Poster 294).
126. Keystone EC, Kavanaugh AF, Sharp JT et al. Inhibition of Radiographic disease progression in patients with long-standing rheumatoid arthritis following 3 years of treatment with adalimumab (HUMIRA®) plus methotrexate. Ann Rheum Dis 2005; 64(Suppl III):419 (Poster SAT0034).
127. van der Heijde D, Klareskog L, Boers M et al. TEMPO Investigators. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 2005;64:1582-7.
128. Geletka RC, St Clair EW. Infliximab for the treatment of early rheumatoid arthritis. Expert Opin Biol Ther 2005;5:405-17.
129. O'Dell JR, Leff R, Paulsen G, Haire C et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: Results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1164-70.
130. Weinblatt ME, Kremer JM, Coblyn JS et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42:1322-8.
131. van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003;62:1195-8.
132. Aletha D, Kapral T, Smolen JS. Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. Ann Rheum Dis 2003;62:482-6.
133. Mavrikakis I, Sfikakis PP, Mavrikakis E et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: A reappraisal. Ophthalmology 2003;110:1321-6.
134. Consenso brasileiro para o diagnóstico e tratamento da artrite reumatóide. Rev Bras Rheumatol 2002;42:355-61.
135. Grove ML, Hassell AB, Hay EM, Shadforth MF. Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. Q J Med 2001;94:309-19.
136. Ortiz Z, Shea B, Suarez Almazor M et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 3, 2000. Oxford: Update Software.
137. Kremer JM, Alarcon GS, Weinblatt ME et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: A multicenter study with literature review. Arthritis Rheum 1997; 40:1829-37.
138. Osiri M, Shea B, Robinson V et al. Leflunomide for the treatment of rheumatoid arthritis: A systematic review and metaanalysis. J Rheumatol 2003;30:1182-90.
139. Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol 2002;29(Suppl 65):33-8.
140. Mangini C, Melo FAF. Artrite reumatóide, terapia imunossupressora e tuberculose. Rev Brás Reumatol 2003;43:11-5.
141. Janssen NM, Genta MS. The effects of Immunosupressive and anti-inflammatory medications on fertility, pregnancy and lactation Arch Intern Med 2000;160:610-19.
142. Doran M, Crowson CS, Pond GR, O'Fallon M, Gabriel SE. Predictors of infections in rheumatoid arthritis. Arthritis and Rheum 2002;46:2294-300.
143. Doran M, Crowson CS, Pond GR, O'Fallon M, Gabriel SE. Frequency of infections in patients with rheumatoid arthritis compared with controls. A population-based study. Arthritis and Rheum 2002;46:2287-93.
144. Ponce de León D, Acevedo-Vázquez E, Sánchez-Torres A et al. Attenuated response to purified protein derivative skin test in rheumatoid arthritis patients. Study in a population with high prevalence of tuberculosis. Ann Rheum Dis 2005;64:1360-1.
145. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161(4 Pt 2):S221-47.
146. Petersson IF. Evolution of team care and evaluation of effectiveness. Curr Opin Rheumatol 2005;17:160-3.
147. Hakkinen A, Sokka T, Kautiainen H et al. Sustained maintenance of exercise induced muscle strength gains and normal bone mineral density in patients with early rheumatoid arthritis: A 5 year follow up. Ann Rheum Dis 2004;63:910-6.
148. de Jong Z, Munneke M, Zwinderman AH et al. Is a long-term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial. Arthritis Rheum 2003;48:2415-24.
149. de Jong Z, Vliet Vlieland TP. Safety of exercise in patients with rheumatoid arthritis. Curr Opin Rheumatol 2005;17:177-82.
150. Li LC, Iversen MD. Outcomes of patients with rheumatoid arthritis receiving rehabilitation. Curr Opin Rheumatol 2005;17:172-6.
151. Casimiro L, Brosseau L, Robinson V et al. Therapeutic ultrasound for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2002;CD003787.
152. Vliet Vlieland TP. Rehabilitation of people with rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003;17:847-61.
153. Shrader JA. Nonsurgical management of the foot and ankle affected by rheumatoid arthritis. J Orthop Sports Phys Ther 1999;29:703-17.
154. Massardo L, Gabriel SE, Crowson CS et al. A population based assessment of the use of orthopedic surgery in patients with rheumatoid arthritis. J Rheumatol 2002;29:52-6.